Goldman Sachs cuts FMC target to EUR 38 for Fresenius Medical Care stock

Published on 10/05/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Berenberg cut its target from EUR 60 to EUR 42 on September 28. Fresenius Medical Care stock costs EUR 40.20 on October 5, 2026 versus EUR 39.60.

Aquarell-Illustration einer stilisierten Niere mit Wassertropfen in Blau- und Türkistönen — Eine zarte Aquarell-Illustration einer stilisierten menschlichen Niere mit Wassertropfen in Blau- und Türkistönen – symbolisch für die Kernkompetenz der Fresenius Medical Care AG (ISIN DE0005785802) in der Nierenersatztherapie, Illustration mit AI erstellt.

Goldman Sachs cut its FMC price target from EUR 39.00 to EUR 38.00 and kept a Neutral rating for Fresenius Medical Care stock on September 30, 2026, according to FinanzNachrichten. The bank cited a limited expected increase in treatment volumes, while its forecast for adjusted operating income was EUR 524.00 million.

Analysts cut targets sharply

The downgrade followed a steeper move by Berenberg. On September 28, 2026, the bank reduced its target from EUR 60.00 to EUR 42.00 and lowered its rating from Buy to Hold, as FinanzNachrichten reported. Analyst Harry Gillis pointed to fading organic growth impulses and the potential continued reduction of Fresenius holdings.

The two target changes point to a divided assessment of FMC. Goldman Sachs sees adjusted operating income at EUR 524.00 million ahead of the November report, while Berenberg describes the shares as fairly valued at its lower EUR 42.00 target.

Profitability remains the counterweight

Fresenius Medical Care said its underlying operating result improved 34 percent in the first half of 2026 after excluding positive TDAPA effects. According to Fresenius Medical Care, higher reimbursement rates and revenue-cycle management supported the increase, and the company confirmed its 2026 outlook.

The company also said its 5008X CAREsystem was available in 227 US clinics and had been used in more than 600,000 treatments. That operating expansion gives the November 3, 2026 third-quarter report a concrete test: treatment volumes must improve while the first-half profitability trajectory holds.

FMC stock gains 1.52 percent

Fresenius Medical Care stock was trading at EUR 40.20 at Lang & Schwarz on October 5, 2026 at 2:11 p.m. CEST, up 1.52 percent versus the prior close of EUR 39.60. The next quarterly report is scheduled for November 3, 2026, according to Fresenius Medical Care. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.